Regeneron at neutral by Merrill

Regeneron Pharmaceuticals Inc: was rated at neutral by Merrill Lynch analyst Hari Sambasivam. The analyst reviews abstracts for the upcoming 2006 ARVO meeting, many of which were for Avastin, far exceeding those for Lucentis, thus providing a sense of the enthusiasm for this agent in the treatment of age related macular degeneration. Estimates indicated up to 20% of new patients are treated with Avastin. Shares of the Tarrytown, N.Y., biotechnology company were down 84 cents, or 4.67%, at $17.16 on volume of 384,617 shares versus the three-month running average of 517,862 shares. (Nasdaq: REGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.